Bortezomib
| Name | Bortezomib |
|---|---|
| Supplier | Cell Signaling Technology |
| Catalog | 2204 |
| Prices | $69.00 |
| Sizes | 2.5 mg |
| Formula | C19H25BN4O4 |
| Molecular Weight | 384.24 g/mol |
| Purity | 99% |
| Description | Bortezomib (C 19 H 25 BN 4 O 4 ), a boronic acid dipeptide, is a specific, potent, and reversable proteasome inhibitor that has also been shown to have a stabilizing effect on proteins that inhibit cell survival and cell cycle progression, such as p53 (1,2). Researchers have demostrated that bortezomib inhibits activation and nuclear translocation of NF-κB, subsequently decreasing early tumor survival (3). The increase in bortezomib-stablilized, misfolded, and ubiquitinated proteins that interfere with cell survival and other important pathways further support its anti-tumor effects (3). |
| Supplier Page | Shop |
Product images
Western blot analysis of extracts from NIH/3T3 cells, untreated (-) or treated (+) with Bortezomib (100 nM, 6 hr), using Ubiquitin Antibody #3933 (left), p53 (1C12) Mouse mAb #2524 (middle), and β-Actin (13E5) Rabbit mAb #4970 (right).
Chemical structure of Bortezomib.
Western blot analysis of L363 cells, untreated (-) or treated (+) with Bortezomib (24 hr) as indicated, using K48-linkage Specific Polyubiquitin Antibody #4289.